MAP2K7 and Schnyder corneal dystrophy: Thus, MEK inhibitors could have a novel multi-facetted therapeutic application for acute vasoocclusive episodes, and my data are a formidable initial step towards testing of existing MEK inhibitors, such as RDEA119 and the FDA-approved trametinib in SCD.